Myeloma Minute: Trends at the Upcoming ASH 2016


Genetic and Molecular Analyses Trending at the Upcoming Annual Meeting of the American Society of Hematology

In his blog this week, IMF Chairman Dr. Brian Durie highlights the most meaningful research from among more than 700 myeloma-related studies to be presented at the upcoming 58th Annual Meeting of the American Society of Hematology (ASH). Genetic and molecular analyses are dominating the research, he notes, but this highly anticipated meeting will also focus on the results of new drug combinations, MRD testing, and a handful of what Dr. Durie calls “clinical pearls.” To read Dr. Durie’s blog, click HERE.


10th Annual Comedy Celebration Is a Hit!

On Saturday, November 5, 2016, Co-founder and President of the International Myeloma Foundation Susie Novis Durie and Chairman of the Board Dr. Brian Durie kicked off the 10th Annual Comedy Celebration at the Wilshire Ebell Theatre in Los Angeles. They gave a warm welcome to the audience and the events generous supporters, and expressed their gratitude to the event’s Chairwoman, Loraine Alterman Boyle. In 2007, Loraine established the Peter Boyle Research Fund in memory of her late husband. Every year she calls upon their friends to join her in raising awareness and money to find a cure. This year’s lineup included host Ray Romano, Jeff Garlin, JB Smoove, Kevin Nealon, Bill Burr and more. View a gallery of photos from the event HERE. Fabulous auction items are still available on CharityBuzz. Bid for tickets to a live taping of Saturday Night Live in New York, or tickets to Hamilton at the Pantages Theatre in LA, & more. The IMF is extremely grateful for your continued support!



Pre-register for the Next "Living Well with Myeloma" Teleconference: Pre-ASH Highlights

Join Dr. Brian G.M. Durie as he moderates “Pre-ASH: What Myeloma Patients & Caregivers Need to Know.” This free teleconference will be held on Thursday, November 17, 2016 at 4:00 p.m. PT / 7:00 p.m. ET. Dr. Durie will focus on the top issues that will be addressed at this year’s American Society of Hematology (ASH) conference, which convenes in San Diego on December 3-6, 2016. Pre-register HERE, and remember it’s free!



The IMF Scores When Boston Celtics Go Behind the Paint in the 2nd Annual '3 Points for Patients' Partnership with Takeda

For the second straight season, every three-point basket made by players of the 17-time champion Boston Celtics will trigger a donation to the International Myeloma Foundation (IMF), courtesy of Takeda and its “3 Points for Patients” campaign, which launches today, Nov. 10. Last year the campaign raised $25,000 for the IMF as the Celtics made 717 three-pointers over the regular season. All money raised this season will once again support IMF’s highly regarded, globally collaborative myeloma research and patient education programs. Learn more HERE.


Seventy-five-year-old Runner and Myeloma Patient Laces Up for His 100th Marathon

On November 20, 2016, multiple myeloma patient Don Wright will be lacing up his sneakers for his 100th marathon in Philadelphia to raise cancer awareness. In 2012, Don Wright doubted that he would be able to reach his first goal: running one marathon in each of the 50 states. After conquering that milestone, Don set another, which he hopes to accomplish with this 100th race. Diagnosed with multiple myeloma at the age of 62, Don was told that his expectation for survival was fewer than five years. Now, 13 years later, he is on oral chemotherapy and has added immune-boosting treatments to his regimen. As Don’s dear wife of 53 years says, “I am grateful that the marvelous medication that my husband started as part of a clinical trial is now approved for use, giving many more people the possibility of a quality of life that we continue to celebrate.” The IMF wishes Don the all the best for when he hits the starting blocks for the Philadelphia Marathon.


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.